Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

OBJECTIVE: We aimed to evaluate the effect of slow-release (SR) Fampridine on multiple outcome measures reflecting different domains, and to compare the responsiveness of the Six Spot Step Test (SSST) and the Timed 25 Foot Walk (T25FW).

METHODS: For this study 108 participants were included. On day 0 they were tested with the T25FW, the SSST, the 9-Hole Peg Test (9-HPT), the 5 Times Sit-To-Stand test (5-STS) and the Symbol Digit Modalities Test (SDMT). Four weeks of treatment with SR Fampridine 10 mg BID was commenced. Participants were tested again after 26-28 days of treatment.

RESULTS: Mean changes observed were: SSST -3.4±6.4s (p<0.001), T25FW -1.2±3.7s (p<0.001), 9-HPT -1.2±6.0s (p<0.001), 5- STS -3.4±7.2s (p<0.001) and SDMT 1.4±4.8 a.u. (p=0.003). Change on the SSST differed significantly from T25FW (SSST 17.0±19.6% vs. T25FW 11.2±17.1%, p=0.0013). Some 48.6% were found to have a meaningful change on the SSST compared with 25.7% on the T25FW. The response to treatment with SR Fampridine did not correlate with age, sex, Expanded Disability Status Scale and disease duration.

CONCLUSION: SR Fampridine treatment has significant effects on different domains including upper and lower body and cognition. Furthermore, the SSST is more responsive to the effect of SR Fampridine than is the T25FW. ClinicalTrials.gov identifier: NCT01656148.

OriginalsprogEngelsk
TidsskriftMultiple Sclerosis Journal
Vol/bind20
Udgave nummer14
Sider (fra-til)1872-1880
ISSN1352-4585
DOI
StatusUdgivet - 22. maj 2014

Fingeraftryk

Exercise Test
Cognition
Outcome Assessment (Health Care)

Citer dette

@article{492b72cc0c844f23b0483538b12c696c,
title = "Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment",
abstract = "OBJECTIVE: We aimed to evaluate the effect of slow-release (SR) Fampridine on multiple outcome measures reflecting different domains, and to compare the responsiveness of the Six Spot Step Test (SSST) and the Timed 25 Foot Walk (T25FW).METHODS: For this study 108 participants were included. On day 0 they were tested with the T25FW, the SSST, the 9-Hole Peg Test (9-HPT), the 5 Times Sit-To-Stand test (5-STS) and the Symbol Digit Modalities Test (SDMT). Four weeks of treatment with SR Fampridine 10 mg BID was commenced. Participants were tested again after 26-28 days of treatment.RESULTS: Mean changes observed were: SSST -3.4±6.4s (p<0.001), T25FW -1.2±3.7s (p<0.001), 9-HPT -1.2±6.0s (p<0.001), 5- STS -3.4±7.2s (p<0.001) and SDMT 1.4±4.8 a.u. (p=0.003). Change on the SSST differed significantly from T25FW (SSST 17.0±19.6{\%} vs. T25FW 11.2±17.1{\%}, p=0.0013). Some 48.6{\%} were found to have a meaningful change on the SSST compared with 25.7{\%} on the T25FW. The response to treatment with SR Fampridine did not correlate with age, sex, Expanded Disability Status Scale and disease duration.CONCLUSION: SR Fampridine treatment has significant effects on different domains including upper and lower body and cognition. Furthermore, the SSST is more responsive to the effect of SR Fampridine than is the T25FW. ClinicalTrials.gov identifier: NCT01656148.",
author = "Jensen, {Henrik Boye} and Mads Ravnborg and Sepehr Mamoei and U Dalgas and Egon Stenager",
note = "{\circledC} The Author(s), 2014.",
year = "2014",
month = "5",
day = "22",
doi = "10.1177/1352458514533844",
language = "English",
volume = "20",
pages = "1872--1880",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "14",

}

Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment. / Jensen, Henrik Boye; Ravnborg, Mads; Mamoei, Sepehr; Dalgas, U; Stenager, Egon.

I: Multiple Sclerosis Journal, Bind 20, Nr. 14, 22.05.2014, s. 1872-1880.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment

AU - Jensen, Henrik Boye

AU - Ravnborg, Mads

AU - Mamoei, Sepehr

AU - Dalgas, U

AU - Stenager, Egon

N1 - © The Author(s), 2014.

PY - 2014/5/22

Y1 - 2014/5/22

N2 - OBJECTIVE: We aimed to evaluate the effect of slow-release (SR) Fampridine on multiple outcome measures reflecting different domains, and to compare the responsiveness of the Six Spot Step Test (SSST) and the Timed 25 Foot Walk (T25FW).METHODS: For this study 108 participants were included. On day 0 they were tested with the T25FW, the SSST, the 9-Hole Peg Test (9-HPT), the 5 Times Sit-To-Stand test (5-STS) and the Symbol Digit Modalities Test (SDMT). Four weeks of treatment with SR Fampridine 10 mg BID was commenced. Participants were tested again after 26-28 days of treatment.RESULTS: Mean changes observed were: SSST -3.4±6.4s (p<0.001), T25FW -1.2±3.7s (p<0.001), 9-HPT -1.2±6.0s (p<0.001), 5- STS -3.4±7.2s (p<0.001) and SDMT 1.4±4.8 a.u. (p=0.003). Change on the SSST differed significantly from T25FW (SSST 17.0±19.6% vs. T25FW 11.2±17.1%, p=0.0013). Some 48.6% were found to have a meaningful change on the SSST compared with 25.7% on the T25FW. The response to treatment with SR Fampridine did not correlate with age, sex, Expanded Disability Status Scale and disease duration.CONCLUSION: SR Fampridine treatment has significant effects on different domains including upper and lower body and cognition. Furthermore, the SSST is more responsive to the effect of SR Fampridine than is the T25FW. ClinicalTrials.gov identifier: NCT01656148.

AB - OBJECTIVE: We aimed to evaluate the effect of slow-release (SR) Fampridine on multiple outcome measures reflecting different domains, and to compare the responsiveness of the Six Spot Step Test (SSST) and the Timed 25 Foot Walk (T25FW).METHODS: For this study 108 participants were included. On day 0 they were tested with the T25FW, the SSST, the 9-Hole Peg Test (9-HPT), the 5 Times Sit-To-Stand test (5-STS) and the Symbol Digit Modalities Test (SDMT). Four weeks of treatment with SR Fampridine 10 mg BID was commenced. Participants were tested again after 26-28 days of treatment.RESULTS: Mean changes observed were: SSST -3.4±6.4s (p<0.001), T25FW -1.2±3.7s (p<0.001), 9-HPT -1.2±6.0s (p<0.001), 5- STS -3.4±7.2s (p<0.001) and SDMT 1.4±4.8 a.u. (p=0.003). Change on the SSST differed significantly from T25FW (SSST 17.0±19.6% vs. T25FW 11.2±17.1%, p=0.0013). Some 48.6% were found to have a meaningful change on the SSST compared with 25.7% on the T25FW. The response to treatment with SR Fampridine did not correlate with age, sex, Expanded Disability Status Scale and disease duration.CONCLUSION: SR Fampridine treatment has significant effects on different domains including upper and lower body and cognition. Furthermore, the SSST is more responsive to the effect of SR Fampridine than is the T25FW. ClinicalTrials.gov identifier: NCT01656148.

U2 - 10.1177/1352458514533844

DO - 10.1177/1352458514533844

M3 - Journal article

C2 - 24852920

VL - 20

SP - 1872

EP - 1880

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 14

ER -